Eli Lilly yesterday announced the decision to stop ... This decision to cease ongoing Phase III development of the schizophrenia treatment is expected to result in a third-quarter charge to ...

Eli Lilly has reportedly commenced Phase III clinical trials of oral medication, orforglipron, for weight loss in India. The ...

The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Eli Lilly is to discontinue development of tabalumab for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) owing to disappointing results in two phase III trials.

Eli Lilly has released detailed results from the Phase III QWINT-2 and QWINT-5 trial showing that its once-weekly insulin efsitora (efsitora alfa) demonstrated a similar reduction in HbA1C levels ...

The endorsement follows Eli Lilly's announcement of successful Phase III trial results for its once-weekly insulin efsitora, which is seen as a strong competitor to Novo Nordisk (NYSE:NVO)'s icodec.

The endorsement follows Eli Lilly's announcement of successful Phase III trial results for its once-weekly insulin efsitora, which is seen as a strong competitor to Novo Nordisk (NYSE:NVO)'s icodec.

Eli Lilly LLY announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora alfa, its once-weekly administered investigational insulin, in adults with ...